News and Press Releases
Almost half of Brits think the Government is doing too little to encourage development of new medicines in the UK
25 January -- London, UK -- Recent YouGov polling commissioned by clinical trials start-up Lindus Health has found that 47% of Brits want the Government to be doing more to...
Category: Pharmaceutical
Posted: January 25, 2024
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year
Annual analysis of data from 95 million patients shows signs of post-pandemic recovery for clinical development industry, but trial cancellation rates at phase 2 remain high 16 January 2024 --...
Category: Clinical Trials
Posted: January 16, 2024
Calypso Enters into Agreement to Be Acquired by Novartis
Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmune indications The acquisition of Calypso gives Novartis...
Category: Biotechnology
Posted: January 8, 2024
Headlands Research Announces Partnership with Sahara Behavioral Health
The collaboration improves access to clinical research and investigational treatments while supporting participant recruitment efforts in Arizona 4 January 2024 -- California, US -- Headlands Research, a leading multinational network...
Category: Clinical Trials
Posted: January 5, 2024
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
5 January 2024 -- Helsinki, Finland -- Nanoform Finland, the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate...
Category: Clinical Trials
Posted: January 5, 2024
Lindus Health and Thirty Madison complete enrolment of personalised dermatology care pilot study
14 December 2023 -- London, UK -- Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialised healthcare brands, have today announced the completion of enrolment of...
Category: Clinical Trials
Posted: December 14, 2023
PlaqueTec recruits first ten patients in BIOPATTERN trial
Trial to investigate atherosclerotic cardiovascular diseases receives MHRA approval to continue recruitment towards 300-patient target Unique PlaqueTec Liquid Biopsy System will be used to collect blood samples containing biomolecules localising...
Category: Clinical Trials
Posted: November 29, 2023
Exonate announces successful completion of phase 1b/2a trial in diabetic macular oedema
Lead ophthalmology candidate EXN407 has potential to be the first topical treatment for diabetic retinopathy/diabetic macular oedema EXN407 met all endpoints and displayed encouraging biological activity in diabetic patients with...
Category: Clinical Trials
Posted: November 28, 2023
Commercial study set up times reduced by a third, according to new data
26 October 2023 -- London, England -- New data from the National Institute for Health and Care Research (NIHR) shows that the National Contract Value Review has significantly reduced the...
Category: Clinical Trials
Posted: October 26, 2023
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT▼(amivantamab) Plus Lazertinib Resulted in 30% Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated NSCLC
Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases Late-breaking results from...
Category: Clinical Trials
Posted: October 24, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...
Category: Clinical Trials
Posted: October 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma · First Significant Improvement in Overall Survival in Two Decades...
Category: Pharmaceutical
Posted: October 23, 2023
AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023
Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...
Category: Clinical Trials
Posted: October 12, 2023
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK
MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland
Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...
Category: Pharmaceutical
Posted: October 9, 2023
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19
mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin phase 3 trial of mRNA-1083 in adults...
Category: Clinical Trials, Drug Discovery
Posted: October 4, 2023
